FDA 2022 Study Warns Against High Risk, High Traffic Fever Screening

By Conor Healy, Published Feb 24, 2022, 11:07am EST (Info+)

FDA scientists published a new fever camera study which found strong performance when strict standards are maintained. However, the study warned about high risk, high traffic screening and did not test the devices or screening methods seen in real world use during the Covid-19 pandemic.

IPVM Image

Inside this report, we examine what the study found, and what it says about fever cameras used during the pandemic.

*** *** ************* *** *********** ** * ******* cameras - *.*.*. ******** ************ (****) - ** **** **** **** ***** subjects. *** **** ****** "****** ********* for ********* ******** **** ************" ***** "may ** ****** ** ******** ******** and ****** ********** ******* *********."

"Little ********" ** ****** ** **** *********

*******, *** ***** **** **** ** past ********* "***** ** ****** ******** that **** ******** [** ***** ****] has **** * *********** ******," ******* because ** ***-******* *******, "*********** **********", and **** ********* **********:

** ******* ****** *********, ***** ********* has **** **** ** ****-******* ***** and ** *** ********* ** ****-**** sites, **** ** ****** ************** ****, hospitals, *** ******** ****** **********, ***there ** ****** ******** **** **** ******** *** **** * *********** ******. This may be due ** **** ** *** ************** ** *********** *************** *** *********** **********, ** **** ** * **** ** ******, ************ ******* ******** ********** *** ********** *** *********. [emphasis added]

**** *****, "*** *** ************* *** also ** ************ ** **** ** the *** ** **** **** ************ performance **************."

******** *** ******* **** "*********", *** study ********** **** *** **** ** "according ** ************ **** *********." ** the ***** ******, **** "******* ******* to ************* *********" ******** ***** ***** ********* **********.

******** ****** ****** ****** ****** *** Covid-19 ********, *** ***-********* ********* ********** *** deployment **** *******, *** ******* ************** ****** ** **** *******.

* ********* *******,************************ ********* *** ********** ** ***** was * ***** ********* ** ************* standards. ***** ************* **** ** ***********(*** ********* ******* *** ******* ********* *** months).

*** ***** **** **** *** ****-******* thermal ******* **** **** ****** ********** than **** ******* **** **** ****** the ********: *** **** ******, **** a *** × *** ***** ******, and *** ******** ******* ***. **** P-series **** * *** × *** pixel ****** (**** *** ***(*) *******).

** **********, *** ******* ****** *** terminal, ***** *** ******* ******* *** "found ** **** **** **% ** NFL ********", *** * *** * 90 ******, ** >* ***** ***** pixels **** *** **** ******. ** some ******* ******, *************** ** ** ***** ** * x * ******.

**** ******* ******** **** **** **** compensating ********** **** **** ************ **** clinical ***. ** ***** ****, **** published* ****-******** ******** ************ **** ********** *********** ************.

Testing **********

*** ***** ****** ****** ***********, **** IRTs **** ********* *** ******** ** non-contact ******** ************ (*****) **** ** the ***** *** **********:

**** ******** *** ****** *********** ** IRTs **** ***** ******** **** **** designed *** ******* ***********,the ******** ******** ** **** **** ****** ** ******* **** **** ** *****. The two IRTs have similar accuracy, and both have better bias and precision than the six models of NCITs, even with the worst regression method.

** *** ******, "**** ***** ** a ****** ****** *** ***** ********* in ****-******* ***** ** ******-**** ********* where *** ****** **** ***** ** justified ** ******* *************."

More ******** ********

**** **** "*********" *******, *** ***** acknowledged **** **** **** **** ***** to ** **** ***** ******* ******* are *********** *** ******** ************. “*********, there *** ** ********* ******* ** evaluate *** ******** ******** ** ****.”

Comments (6)

****** ***** **** ***** **** **** month *** * **** *** ******* complex ***** * ** **** **** me **** *** "***** ********" ***. They **** ****** ***** ** ** demanding **** **** ***** ****! * even ******* *** *** ********** ** them *** ***** *** *********** *** that *** ***** *** ** *** wrong ********* ** ************* **** **** properly. **** ****** *** **** *** facing *** *******. * **** *** a **** ***** ***'* **** ** I *** * *** ***** *** one ** **** **** * *** below ******!

Agree
Disagree
Informative: 2
Unhelpful
Funny

*** **** *** ******* ** **** a *** ****** *********** *** ******* others ** ****?

Agree
Disagree
Informative
Unhelpful
Funny

******* ** ****** **** ** ** go ** *** ********* **** ** they **** ******* * *** **** had * ***** ****. * ***** I ***’* ********** **** ********. *** you ****** ** ******* *** * fever **** ****** *** ** ** the ****** ** ********?? **** **** was ***** * *** ********** **** covid *** ******* **** ***** ****** from *****.

Agree: 2
Disagree
Informative
Unhelpful
Funny

*’* ****** **** *** ** ******* at *****.

Agree
Disagree
Informative
Unhelpful
Funny

*****, * ******* **** *** * place ** **** *** ***

Agree
Disagree
Informative
Unhelpful
Funny

******. ***** *** ***** ** * beat **** **** ****.

Agree
Disagree
Informative
Unhelpful
Funny
Login to read this IPVM report.
Why do I need to log in?
IPVM conducts reporting, tutorials and software funded by subscriber's payments enabling us to offer the most independent, accurate and in-depth information.
Loading Related Reports